Results 171 to 180 of about 128,640 (296)

Parental Communication With Children Around Obesity Management Medications, Weight Loss, and Health Behavior Change

Obesity, EarlyView.
ABSTRACT Objective This study aimed to describe parental communication with children around obesity management medications (OMMs) and child, parent, and family factors associated with communication. Methods Parents (N = 211; 80% mothers; 89% White) prescribed OMMs at a medical center participated in a survey about communication with children about OMM ...
Keeley J. Pratt, Selena Gonzlez‐Jordan, Sabrena F. Noria, Joseph A. Skelton   +3 more
wiley   +1 more source

Distribution of glucagon-like peptide 1 receptor and insulin in phaeochromocytomas. [PDF]

Endocr Connect
Følling I, Selle ML, Nilsen HR, Wennerström AB, Nilsen HL, Eide TJ.   +5 more
europepmc   +1 more source

Cardiovascular Disease and Obesity Medications in Older Women by Obesity‐Related Cancers Status: SEER‐Medicare 2007–2015

Obesity, EarlyView.
ABSTRACT Objective This study evaluated the association between antiobesity medications (AOM) and incident cardiovascular disease (CVD) among older women, examining this relationship within and across survivors of obesity‐related cancers (ORCa) and age‐matched cancer‐free populations.
David S. Lopez, Omer Abdelgadir, Yuanyi Zhang, Jesús Gibran Hernández‐Pérez, Maryam R. Hussain, Mohanad Albayyaa, Rasmi Nair, Yong‐Fang Kuo, Jaime P. Almandoz, Lindsay G. Cowell, Sarah E. Messiah   +10 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists in Obesity-Induced Respiratory Pathophysiology. [PDF]

Acta Physiol (Oxf)
Ruiz MA, Furquim THDC, Davaanyam D, Williams NR, Polotsky VY, Amorim MR.   +5 more
europepmc   +1 more source

Monogenic and syndromic obesity in children: Clinical recognition, genetics, and precision management

Pediatric Investigation, EarlyView.
Monogenic and syndromic obesity in children often arises from defects in the leptin–melanocortin pathway. Understanding these rare genetic causes not only clarifies mechanisms of appetite regulation but also enables precision therapies, offering hope beyond lifestyle interventions.
Hadel Khalil, Eugene Feigin, Hussein Zaitoon   +2 more
wiley   +1 more source

Prescribing Trends in Glucagon-Like Peptide-1 Medications Among Pregnant and Postpartum Persons. [PDF]

Obstet Gynecol
Lessard C, Cary C, In A, Steinle J, Lin BY, Kablinger AS, Grucza RA, Bello JK, Galati BM, Kimmel M, Bruno AM, Kelly JC, Xu KY.   +12 more
europepmc   +1 more source

Glucagon-like Peptide-1 Measurement [PDF]

, 2020
openaire   +1 more source

Fast Quantitative Evaluation of the Amelioration Effect in MASLD During Semaglutide Treatment Using Ultrasound‐Derived Fat Fraction and Fat‐to‐Muscle Ratio

Portal Hypertension &Cirrhosis, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a chronic liver disease. Research into a feasible, rapid, and effective assessment method is crucial for evaluating the therapeutic effects of semaglutide in MASLD. This prospective study utilized ultrasound‐derived fat fraction measurement and fat‐to‐muscle ratio to evaluate hepatic ...
Yunlin Huang, Ruping Yang, Ying Wang, Xiu‐Yun Lu, Li Wei, Rui Cheng, Juan Cheng, Yijie Qiu, Shiwen Wang, Bo Li, Yi Dong   +10 more
wiley   +1 more source

The Role of Glucagon-like Peptide-1 in the Pathophysiology of Heart Failure: A Special Focus. [PDF]

Card Fail Rev
Rakisheva A, Zatsarinnyy A.
europepmc   +1 more source

From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies

Portal Hypertension &Cirrhosis, EarlyView.
This review examines the epidemiological shift from hepatitis B virus (HBV) to metabolic dysfunction‐associated steatotic liver disease (MASLD) as the leading cause of cirrhosis globally. It highlights the distinct pathogenic mechanisms between HBV and MASLD cirrhosis and discusses evolving diagnostic tools and therapeutic strategies tailored to the ...
Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang   +5 more
wiley   +1 more source